Xu-Feng Chen Selected Research

LC capilliposide

1/2017

Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xu-Feng Chen Research Topics

Disease

2	Heart Arrest (Cardiac Arrest) 01/2018 - 01/2017
2	Neoplasms (Cancer) 11/2017 - 01/2017
1	Magnesium Deficiency (Deficiency, Magnesium) 01/2020
1	Starvation 09/2019
1	Hypochromic Anemia (Chlorosis) 09/2019
1	Adenocarcinoma 11/2017
1	Neoplasm Metastasis (Metastasis) 11/2017
1	Prostatic Neoplasms (Prostate Cancer) 11/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017

Drug/Important Bio-Agent (IBA)

1	CarbohydratesIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Chlorophyll AIBA 09/2019
1	BoronIBA 09/2019
1	Histone Deacetylase InhibitorsIBA 11/2017
1	Vorinostat FDA Link 11/2017
1	AndrogensIBA 11/2017
1	Biological ProductsIBA 11/2017
1	Therapeutic UsesIBA 11/2017
1	Gefitinib (Iressa)FDA Link 01/2017
1	LC capilliposideIBA 01/2017

Therapy/Procedure

1	Extracorporeal Membrane Oxygenation 01/2018
1	Drug Therapy (Chemotherapy) 11/2017
1	Therapeutics 11/2017
1	Cardiopulmonary Resuscitation (CPR) 01/2017